WHO and UNAIDS welcome findings of trials assessing impact of male circumcision on HIV risk

The World Health Organization (WHO) and the UNAIDS Secretariat have welcomed the publication in The Lancet of the detailed findings of two trials undertaken in Kenya and Uganda to determine whether male circumcision has a protective effect against acquiring HIV infection.

Funded by the US National Institutes of Health, the trials were terminated early on 12 December 2006 on the recommendation of their Data and Safety Monitoring Board. The findings of the two trials support the results of the South Africa Orange Farm Intervention Trial, funded by the French National Agency for Research on AIDS (ANRS), which were published in late 2005. Together the three studies, which enrolled more than 10 000 participants, provide compelling evidence of a 50 to 60% reduction in heterosexual HIV transmission to men.

"These findings are a very important contribution to HIV prevention science. Male circumcision has major potential for the prevention of HIV infection", said Kevin De Cock, Director of the WHO HIV/AIDS Department.

WHO and the UNAIDS Secretariat have convened an international consultation in early March to examine the results of the new trials and assess their policy and programmatic implications for countries. The consultation will address a range of policy, operational and ethical issues that will help guide decisions about where and how male circumcision can be best implemented, promoted and safely performed. Based on the recommendations of the experts, a statement will be issued.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New two-dose HIV vaccine strategy shows promise for stronger immune response